Ligand Screening System for the RXRα Heterodimer Using the Fluorescence RXR Agonist CU-6PMN
Mayu Kawasaki1, Tomoharu Motoyama1, Shoya Yamada2
1Graduate School of Integrated Pharmaceutical and Nutritional Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.
Abstract:
Retinoid X receptor (RXR), a nuclear receptor (NR) that regulates transcription of target genes in a ligand binding-dependent manner, is of interest as a drug target. RXR agonists have been developed as therapeutic agents for cutaneous invasive T-cell lymphoma (e.g., bexarotene (1)) and investigated as potential anti-inflammatory agents. Screening systems for the binding of RXR alone have been reported. However, although RXRs function as RXR heterodimers, information on systems to evaluate the differential binding of RXR agonists as RXR heterodimers has not been available until recently. Here we show that the fluorescent RXR agonist CU-6PMN (3), designed by our group, can be useful for assessing RXR binding to PPARγ/RXRα, and that the binding data differ from those of RXRα alone. This screening method opens a new avenue for binding assays for RXR heterodimers.
Insights
This study introduces a new fluorescent agonist, CU-6PMN, for evaluating Retinoid X Receptor (RXR) heterodimer binding. This method reveals differential binding data compared to RXR alone, advancing drug discovery for nuclear receptor targets.
Area of Science:
- Molecular Biology
- Pharmacology
- Biochemistry
Background:
- Retinoid X Receptor (RXR) is a nuclear receptor regulating gene transcription, making it a significant drug target.
- RXR agonists like bexarotene are used for cutaneous T-cell lymphoma and explored for anti-inflammatory properties.
- Existing screening systems primarily assess RXR binding alone, lacking methods for RXR heterodimer interactions.
Purpose of the Study:
- To develop and validate a novel screening system for assessing the differential binding of RXR agonists to RXR heterodimers.
- To demonstrate the utility of a newly designed fluorescent RXR agonist, CU-6PMN, in these assays.
Main Methods:
- Design and synthesis of a fluorescent RXR agonist, CU-6PMN.
- Utilizing CU-6PMN in binding assays to evaluate RXR heterodimer interactions, specifically with PPARγ/RXRα.
- Comparison of binding data obtained for RXR heterodimers versus RXR alone.
Main Results:
- The fluorescent RXR agonist CU-6PMN effectively assesses RXR binding to the PPARγ/RXRα heterodimer.
- Binding data obtained using CU-6PMN with RXR heterodimers differed significantly from data obtained with RXR alone.
- This highlights the importance of evaluating RXR agonists in the context of their heterodimeric partners.
Conclusions:
- A novel fluorescent probe and screening method have been established for evaluating RXR heterodimer binding.
- This approach provides crucial insights into the differential pharmacology of RXR agonists when complexed in heterodimers.
- The developed screening method offers a new avenue for drug discovery targeting RXR heterodimers.
More Related Videos
08:46A "Dual-Addition" Calcium Fluorescence Assay for the High-Throughput Screening of Recombinant G Protein-Coupled Receptors
Published on: December 2, 2022
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018